|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MRPL28 |
Gene summary for MRPL28 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MRPL28 | Gene ID | 10573 |
| Gene name | mitochondrial ribosomal protein L28 | |
| Gene Alias | MAAT1 | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | Q13084 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10573 | MRPL28 | LZE2T | Human | Esophagus | ESCC | 8.25e-06 | 8.81e-01 | 0.082 |
| 10573 | MRPL28 | LZE4T | Human | Esophagus | ESCC | 3.55e-18 | 5.11e-01 | 0.0811 |
| 10573 | MRPL28 | LZE7T | Human | Esophagus | ESCC | 9.87e-19 | 7.03e-01 | 0.0667 |
| 10573 | MRPL28 | LZE8T | Human | Esophagus | ESCC | 2.95e-25 | 7.90e-01 | 0.067 |
| 10573 | MRPL28 | LZE20T | Human | Esophagus | ESCC | 1.27e-07 | 4.07e-01 | 0.0662 |
| 10573 | MRPL28 | LZE22D1 | Human | Esophagus | HGIN | 2.94e-07 | 2.91e-01 | 0.0595 |
| 10573 | MRPL28 | LZE22T | Human | Esophagus | ESCC | 1.11e-06 | 5.76e-01 | 0.068 |
| 10573 | MRPL28 | LZE24T | Human | Esophagus | ESCC | 5.31e-28 | 6.87e-01 | 0.0596 |
| 10573 | MRPL28 | LZE21T | Human | Esophagus | ESCC | 2.05e-03 | 4.84e-01 | 0.0655 |
| 10573 | MRPL28 | LZE6T | Human | Esophagus | ESCC | 5.71e-10 | 5.43e-01 | 0.0845 |
| 10573 | MRPL28 | P1T-E | Human | Esophagus | ESCC | 2.17e-17 | 7.44e-01 | 0.0875 |
| 10573 | MRPL28 | P2T-E | Human | Esophagus | ESCC | 6.47e-82 | 1.39e+00 | 0.1177 |
| 10573 | MRPL28 | P4T-E | Human | Esophagus | ESCC | 2.94e-71 | 1.66e+00 | 0.1323 |
| 10573 | MRPL28 | P5T-E | Human | Esophagus | ESCC | 3.33e-38 | 8.32e-01 | 0.1327 |
| 10573 | MRPL28 | P8T-E | Human | Esophagus | ESCC | 2.36e-35 | 6.78e-01 | 0.0889 |
| 10573 | MRPL28 | P9T-E | Human | Esophagus | ESCC | 3.52e-29 | 6.33e-01 | 0.1131 |
| 10573 | MRPL28 | P10T-E | Human | Esophagus | ESCC | 1.93e-25 | 4.50e-01 | 0.116 |
| 10573 | MRPL28 | P11T-E | Human | Esophagus | ESCC | 1.90e-17 | 6.79e-01 | 0.1426 |
| 10573 | MRPL28 | P12T-E | Human | Esophagus | ESCC | 8.47e-59 | 1.14e+00 | 0.1122 |
| 10573 | MRPL28 | P15T-E | Human | Esophagus | ESCC | 3.01e-56 | 1.08e+00 | 0.1149 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0301039 | Esophagus | HGIN | Ribosome | 108/1383 | 167/8465 | 1.44e-45 | 4.71e-43 | 3.74e-43 | 108 |
| hsa03010115 | Esophagus | HGIN | Ribosome | 108/1383 | 167/8465 | 1.44e-45 | 4.71e-43 | 3.74e-43 | 108 |
| hsa03010211 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
| hsa03010310 | Esophagus | ESCC | Ribosome | 129/4205 | 167/8465 | 1.43e-13 | 3.43e-12 | 1.75e-12 | 129 |
| hsa0301022 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
| hsa0301032 | Liver | Cirrhotic | Ribosome | 127/2530 | 167/8465 | 2.12e-35 | 7.06e-33 | 4.35e-33 | 127 |
| hsa0301042 | Liver | HCC | Ribosome | 128/4020 | 167/8465 | 7.32e-15 | 2.23e-13 | 1.24e-13 | 128 |
| hsa0301052 | Liver | HCC | Ribosome | 128/4020 | 167/8465 | 7.32e-15 | 2.23e-13 | 1.24e-13 | 128 |
| hsa0301030 | Oral cavity | OSCC | Ribosome | 128/3704 | 167/8465 | 2.42e-18 | 1.62e-16 | 8.25e-17 | 128 |
| hsa03010114 | Oral cavity | OSCC | Ribosome | 128/3704 | 167/8465 | 2.42e-18 | 1.62e-16 | 8.25e-17 | 128 |
| hsa03010210 | Oral cavity | LP | Ribosome | 127/2418 | 167/8465 | 1.22e-37 | 4.05e-35 | 2.61e-35 | 127 |
| hsa0301038 | Oral cavity | LP | Ribosome | 127/2418 | 167/8465 | 1.22e-37 | 4.05e-35 | 2.61e-35 | 127 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MRPL28 | SNV | Missense_Mutation | novel | c.468G>T | p.Lys156Asn | p.K156N | Q13084 | protein_coding | tolerated(0.06) | probably_damaging(0.973) | TCGA-E9-A5FL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPL28 | SNV | Missense_Mutation | rs747105916 | c.50G>A | p.Arg17Gln | p.R17Q | Q13084 | protein_coding | tolerated_low_confidence(0.27) | benign(0.007) | TCGA-OL-A5RU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
| MRPL28 | SNV | Missense_Mutation | novel | c.340N>C | p.Phe114Leu | p.F114L | Q13084 | protein_coding | tolerated(1) | benign(0) | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| MRPL28 | SNV | Missense_Mutation | rs772941032 | c.196C>T | p.Pro66Ser | p.P66S | Q13084 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| MRPL28 | SNV | Missense_Mutation | rs779828943 | c.511C>G | p.Arg171Gly | p.R171G | Q13084 | protein_coding | deleterious(0.04) | possibly_damaging(0.561) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| MRPL28 | SNV | Missense_Mutation | rs756831724 | c.418N>A | p.Gly140Arg | p.G140R | Q13084 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPL28 | SNV | Missense_Mutation | rs201250294 | c.550N>T | p.Arg184Trp | p.R184W | Q13084 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-AX-A2HA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| MRPL28 | SNV | Missense_Mutation | novel | c.222N>T | p.Glu74Asp | p.E74D | Q13084 | protein_coding | tolerated(0.06) | possibly_damaging(0.851) | TCGA-BG-A221-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MRPL28 | SNV | Missense_Mutation | rs765442445 | c.544N>A | p.Glu182Lys | p.E182K | Q13084 | protein_coding | tolerated(0.85) | benign(0.02) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| MRPL28 | SNV | Missense_Mutation | c.446C>T | p.Pro149Leu | p.P149L | Q13084 | protein_coding | deleterious(0) | probably_damaging(0.96) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |